Einav Nili Gal-Yam
Advertisement
Articles by Einav Nili Gal-Yam
16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation
ByMatthew P. Goetz, MD,Seth A. Wander,Thomas Bachelot,Gerald Batist,Javier Cortés, MD,Massimo Cristofanilli, MD,Giuseppe Curigliano,Alexandre de Nonneville,Einav Nili Gal-Yam,Komal Jhaveri,Cynthia X. Ma, MD, PhD,Heather A. Parsons, MD, MPH,Hope S. Rugo, MD,Sarah L. Sammons,Daniel G. Stover,Chris Twelves, MD, FRCP,Aditya Bardia, MD, MPH, FASCO,Paul V. Plourde,David J. Portman,Senthil Damodaran
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
ASH 2025: Key Anticipated Updates in the Leukemia Landscape
2
Fixed-Duration Venetoclax Combos Show Noninferior PFS to Ibrutinib in CLL
3
Real-World Elranatamab Maintains Responses in Elderly, Frail R/R Multiple Myeloma
4
Survival Benefit Seen With Cilta-Cel in Earlier Lines of Myeloma Treatment
5
